- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Day One Biopharmaceuticals Inc (DAWN)
The Day One Biopharmaceuticals share price today is 21.53 %REPORT_CURRENCY%, view NASDAQ DAWN stock exchange data. Track the latest Day One Biopharmaceuticals share price with real-time updates on DAWN stock performance including market cap, day range, 52-week range and dividend yield. Access DAWN charts, earnings dates and analyst estimates to support your investment decisions.
21.53
+0.04(+0.19%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.49
21.53
52 wk Range
5.64
21.53
Showing Day One Biopharmaceuticals historical data. For real-time data please try another search
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.4921.53
52 wk Range
5.6421.53
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DAWN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
21.50
Downside
-0.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Form 8K Day One Biopharmaceuticals Inc For: 23 April
- Investing.com
- Form 13G DAY ONE BIOPHARMACEUTICALS INC For: 7 April
- Investing.com
- Form 8K Day One Biopharmaceuticals Inc For: 23 April
- Investing.com
- Form 13D/A Day One Biopharmaceuticals For: 13 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 23, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC.
Day One Biopharmaceuticals Inc Earnings Call Summary for Q3/2025
- Day One Biopharmaceuticals reported Q3 2025 EPS of -$0.19 (beating -$0.29 forecast) and revenue of $39.8M (exceeding $38.19M forecast), despite stock declining 0.14% in regular trading.
- The company raised full-year 2025 revenue guidance to $145-$150M following a 15% quarter-over-quarter increase in net product revenue to $38.5M, driven by OJEMDA's commercial success.
- Key operational achievements include an 18% increase in total prescriptions and 20% rise in new patient starts, with OJEMDA revenue exceeding combined cost of sales and SG&A for the first time.
- Despite positive performance, the stock remains near its 52-week low of $5.64, reflecting investor caution amid broader market conditions affecting the biotech sector.
- The company maintains a strong financial position with $451.6M in cash reserves and no debt, while focusing on pipeline advancement and establishing OJEMDA as a standard of care.
Last Updated: 05-11-2025, 04:18 am
Read Full TranscriptCompare DAWN to Peers and Sector
Metrics to compare | DAWN | Peers Peers - average of corresponding metrics from companies closely matching DAWN: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDAWNPeersSector |
|---|---|---|---|---|
P/E Ratio | −20.7x | 0.0x | −0.4x | |
PEG Ratio | 13.49 | 0.00 | 0.00 | |
Price/Book | 5.0x | 0.0x | 2.6x | |
Price / LTM Sales | 14.1x | 0.0x | 3.1x | |
Upside (Analyst Target) | −0.1% | 0.0% | 47.4% | |
Fair Value Upside | Unlock | 0.0% | 7.0% | Unlock |
Analyst Ratings
0 Buy
4 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 21.50
(-0.14% Downside)
Earnings
Latest Release
24-02-2026
EPS / Forecast
-0.21 / -0.19
Revenue / Forecast
52.8M / 45.86M
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.